Pressmeddelande -
United States Patent and Trademark Office issues OnDosis first patent April 11th
Gothenburg, Sweden – April 12th 2023
OnDosis today announced that the company´s first patent was issued by the United States Patent and Trademark Office (USPTO) on April 11th 2023, with the patent number 11622914.
The issued patent covers the Dosage Manager device platform developed by OnDosis for dosing of oral solid medicines in the form of pellets. The issued patent is the first relating to OnDosis innovative device and its core design and functionality, and the company expects further patents to follow in due course from the company’s extensive patent portfolio.
“We are very pleased with this first issued patent for our invention, the Dosage Manager, which is now at final stage of development and expected to undergo a regulatory approval process in the US during 2024 as a part of a drug/device combination aimed to improve treatment of patients with ADHD”, says Martin Olovsson, CEO at OnDosis, and continues “the US is the most important market for us at this stage since this is where we target our first launch, and due to its size and its openness to innovation. We are very excited by the fact that our first issued patent is in the US.”
The OnDosis Dosage Manager is developed as a device platform technology which can be adopted and scaled across a multitude of disease areas. OnDosis collaborates with leading pharmaceutical companies to bring drug/device combination products to market for the benefits of patients, the healthcare system and society.
The benefit of a Dosage Manager drug/device combination is the ability to deliver flexible, precise, and individual dosing of medicines where dose titration and adjustments are essential to reach desired outcomes. Other benefits are the ability to, through connection with digital services, engage patients into their care and to provide better insights for healthcare professionals on the relation between dosage and outcomes. In addition, the Dosage Manager promotes safe use through features ensuring that the right dose is taken by the right patient, at the right time. Medicines delivered in the form of pellets are easier to swallow, something that can be valuable when delivering medicines for children.
OnDosis have several development projects ongoing in collaboration with Tiefenbacher Group (Hamburg, Germany) under the OYSTA®brand, and with other undisclosed biopharmaceutical companies. The first project in collaboration with Tiefenbacher is expected to reach the US market in 2025, aiming to improve treatment for patients with ADHD.
Besides ADHD, other CNS related diseases as well as cardiovascular, oncology, orphan and pediatric indications are in focus for future developments.
Ämnen
Founded as a spin-out from AstraZeneca in 2017, OnDosis is a Swedish start-up addressing one of the major opportunities in healthcare; personalized dosage of medicines. The proprietary technology platform is centered around a connected handheld dosing device that delivers tailored doses of oral medicines. By combining individual dosing of traditional drug-based medicines augmented by digital therapeutics, OnDosis opens a new chapter in personalized medicine where the mission is to improve patients’ life through delivering the perfect dosage; individualized, intuitive, and intelligent.
